LISINOPRIL TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

LISINOPRIL (LISINOPRIL DIHYDRATE)

可用日期:

COBALT PHARMACEUTICALS COMPANY

ATC代码:

C09AA03

INN（国际名称）:

LISINOPRIL

剂量:

10MG

药物剂型:

TABLET

组成:

LISINOPRIL (LISINOPRIL DIHYDRATE) 10MG

给药途径:

ORAL

每包单位数:

30/100/500

处方类型:

Prescription

治疗领域:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

產品總結:

Active ingredient group (AIG) number: 0121550001; AHFS:

授权状态:

CANCELLED PRE MARKET

授权日期:

2017-09-01

产品特点

______________________________________________________________________________________________
_
_LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 1 of 44 _
_ _
_ _
PRODUCT MONOGRAPH
PR
LISINOPRIL
Lisinopril Tablets, USP
5 mg, 10 mg and 20 mg
(of Lisinopril as Lisinopril Dihydrate)
Angiotensin Converting Enzyme Inhibitor
Cobalt Pharmaceuticals Company
6500 Kitimat Road
Mississauga, Ontario
Canada, L5N 2B8
CONTROL NUMBER: 172480
Date of Revision:
March 4, 2014
______________________________________________________________________________________________
_
_LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 2 of 44 _
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
11
DRUG INTERACTIONS
.........................................................................................................
17
DOSAGE AND ADMINISTRATION
.....................................................................................
20
OVERDOSAGE
.......................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 23
STORAGE AND STABILITY
.................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.........................